According to the Market Statsville Group (MSG), the Global Uterotonic Agent Market size is expected to grow at a CAGR of 7.9% from 2024 to 2033.

A uterotonic agent is a medication or substance used during labor and delivery to create or strengthen uterine contractions and to prevent or treat postpartum hemorrhage. These agents are essential in obstetrics and gynecology as they help a safe and successful childbirth process. The uterotonic agents stimulate the contraction of the uterine muscles, and myometrium, and thus promote effective labor. These agents aid in the progression of labor, support cervical dilation, and contribute to the delivery of the baby by increasing the intensity, frequency, and duration of uterine contractions.

The uterotonic agent market is experiencing significant growth driven by global population growth, rising awareness of maternal healthcare, and advancements in medical technologies. The growing population and improved healthcare facilities in emerging nations have increased the demand for uterotonic agents. According to the United Nations report, as of mid-November 2022, the global human population has reached 8.0 billion, a significant increase from an estimated 2.5 billion in 1950. Over the past few decades, the population has grown rapidly, with an additional 1 billion people added since 2010 and 2 billion since 1998. Projections indicate that the world's population is expected to continue its upward trajectory. Over the next 30 years, it is anticipated to increase by nearly 2 billion individuals, reaching 9.7 billion by 2050.

Furthermore, the growing concern regarding the crucial nature of maternal healthcare and postpartum hemorrhage prevention has fueled market growth. Medical technology advancements have been critical in the development of novel uterotonic agents. The addition of oxytocin and prostaglandin analogs improved uterotonic agents' effectiveness and safety, resulting in widespread use. Compared to traditional methods, these agents provide better control over uterine contractions and have fewer side effects.

Report Scope of the Global Uterotonic Agent Market

This market research study categorizes the uterotonic agent market-based on drug, indication, route of administration, distribution channel, and end-user area at the regional and global levels.

By Drug Outlook (Sales, USD Million, 2019-2033)

• Carboprost
• Mifepristone
• Methylergonovine
• Dinoprostone
• Dinoprostone
• Others

By Indication Outlook (Sales, USD Million, 2019-2033)

• Postpartum Hemorrhage
• Abortion
• Labor
• Others

By Route of Administration Outlook (Sales, USD Million, 2019-2033)

• Oral
• Parenteral
• Others

By Distribution Channel Outlook (Sales, USD Million, 2019-2033)

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By End-User Outlook (Sales, USD Million, 2019-2033)

• Hospitals
• Homecare
• Speciality Centres
• Others

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Egypt
  • Rest of MEA

Uterotonic Agent Market Segmental and Regional Analysis, 2024-2033

Based on end-user, the uterotonic agent market is classified into hospitals, homecare, speciality centres, and others. Amoong these end-users, the hospitals segment accounted for over 55% market share in 2023. Due to the accessibility of skilled healthcare professionals, advanced medical equipment, and a safe environment, pregnant women frequently choose hospitals for the delivery of their babies. As a result, hospitals are in high demand for uterotonic agents to induce or augment labor, manage postpartum hemorrhage, and ensure both the mother and baby's well-being. The hospitals have well-established facilities and resources to deal with difficult childbirth scenarios. The presence of specialized healthcare teams, such as obstetricians, midwives, and anesthesiologists, also favors segmental growth in the market.

Based on the regions, the global uterotonic agent market has been segmented across Europe, North America, the Middle East & Africa, Asia-Pacific, and South America. Asia Pacific accounted for the largest market share in 2023. With large populations such as China and India, the huge number of births contributes to the need for uterotonic agents to facilitate labor and ensure safe deliveries. The rising birth rate in many Asian countries increases demand for these agents. Further, there is a growing awareness in the Asia Pacific region of the crucial nature of maternal healthcare and the prevention of postpartum hemorrhage. Governments and healthcare organizations are emphasizing strengthening maternal healthcare services, including uterotonic agent availability and accessibility. This increased awareness, combined with a desire to lower maternal mortality rates, has resulted in an increase in demand for these agents.

Uterotonic Agent Market Key Players, 2023

The major players in the global uterotonic agent market are:

• Nexus Pharmaceuticals
• Pfizer Inc
• Dr. Reddy's Laboratories Ltd
• Corcept
• GenBioPro
• Teva Pharmaceutical Industries Ltd
• Amneal Pharmaceuticals Inc
• Lupin
• Daiichi Sankyo Company Limited
• Ferring B.V.
• Novartis International AG
• Merck & Co., Inc.
• Mylan N.V
• Fresenius Kabi AG
• Bayer AG
• Sanofi S.A.
• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson)
• Bristol-Myers Squibb Company
• Hikma Pharmaceuticals PLC
• Aspen Pharmacare Holdings Limited
• Sun Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Zydus Cadila
• Cipla Limited
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories
• Hologic, Inc.
• Lactalis International

Recent Developments

• In March 2023, Ferring Pharmaceuticals launched uterotonic agent, misoprostol vaginal tablets, a new formulation of misoprostol specifically designed to prevent postpartum hemorrhage.
• In March 2023, Mylan acquired Mithra Pharmaceuticals, a developer of uterotonic agents. The acquisition will allow Mylan to expand its portfolio of uterotonic agents and reach a wider audience.
• In April 2023, Ferring Pharmaceuticals partnered with MSD to offer misoprostol vaginal tablets through MSD's global distribution network. The partnership will make it easier for patients to access misoprostol vaginal tablets and provide healthcare providers with a new way to prevent postpartum hemorrhage.